Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
| Status: | Completed |
|---|---|
| Conditions: | Cardiology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | September 2007 |
| End Date: | April 2008 |
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular
mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will
be treated for 12 weeks.
mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will
be treated for 12 weeks.
Inclusion Criteria:
- macular edema due to diabetic retinopathy
Exclusion Criteria:
- vision loss from other ocular disease
- intraocular surgery within 3 months
- intraocular anti-VEGF or steroids within 3 months
- HbA1c >12
We found this trial at
3
sites
733 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials